The outbreak of drug-resistant infections in U.S. hospitals and schools may provide both Johnson & Johnson and Pfizer Inc. with a $1 billion windfall in a market that analysts expect will double in five years.
J&J, the world's largest health-products company, and Pfizer, the biggest drugmaker, are poised to release new antibiotics next year to treat MRSA, or methicillin-resistant Staphylococcus aureus. The germ sickens about 2 million Americans annually, costs about $20 billion a year to treat, and has reinvigorated the search for new antibiotics.
More at Bloomberg
This one's just for you Dave!
No comments:
Post a Comment